Jun 15, 2020
Arena Pharmaceuticals Appoints Biotech Executive Katharine Knobil, M.D., to Board of Directors
Jun 08, 2020
Arena Pharmaceuticals Announces R&D Leadership Transition
May 26, 2020
Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for Atopic Dermatitis, Provides Program Updates
Apr 06, 2020
The Global Pulmonary Arterial Hypertension Market is expected to grow from USD 7,196.48 Million in 2019 to USD 9,925.12 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 5.50%
Mar 30, 2020
Arena Pharmaceuticals Names James C. Mullen as an Independent Senior Advisor
Feb 11, 2020
Arena Pharmaceuticals' Presence at the European Crohn's and Colitis Organisation (ECCO) Congress Further Highlights Commitment to the GI Community
Jan 16, 2020
FDA Grants Fast Track Designation to Arena Pharmaceuticals' APD418 for Development in Decompensated Heart Failure Patients
Jan 13, 2020
Arena Pharmaceuticals Appoints Joan Schmidt as Executive Vice President, General Counsel and Secretary
Jan 02, 2020
Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
Oct 22, 2019
Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
Oct 18, 2019
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Bolsters Commitment to the Gastrointestinal Disease Community
Aug 07, 2019
Arena Reports Second Quarter Financial Results with Strong Liquidity Position, and Initiation of Etrasimod ELEVATE UC 52 and Olorinab CAPTIVATE Trials
May 17, 2019
Arena Pharmaceuticals' Presence at Digestive Disease Week (DDW) Reinforces Commitment to the Gastrointestinal Disease Community
May 08, 2019
Arena Pharmaceuticals Provides Corporate Update and Reports First Quarter 2019 Financial Results
Mar 08, 2019
Arena Pharmaceuticals Presented New Phase 2 Data for Etrasimod and Olorinab at the 14th Congress of European Crohn's and Colitis Organisation
Feb 07, 2019
Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congress
Jan 24, 2019
Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
Jan 07, 2019
Arena Pharmaceuticals Reports Positive Long-Term Data from the Open-Label Extension of the Phase 2 OASIS Trial Evaluating Etrasimod for Treatment of Ulcerative Colitis
Dec 17, 2018
Arena Pharmaceuticals Appoints Experienced Life Sciences Industry Finance Executive Manmeet S. Soni to Board of Directors
Nov 26, 2018
Arena Pharmaceuticals Expands Senior Management Team to Support Commercialization and Medical Affairs